Lineage Cell Therapeutics, Inc. Cash and Restricted Cash
Lineage Cell Therapeutics, Inc. (LCTX) had Cash and Restricted Cash of $37.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.32M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.98M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $37.92M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $36.48M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $41.32M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $40.98M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $42.77M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $48.34M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $46.35M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $28.31M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $30.17M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $44.12M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $35.99M 10-K · filed 2026-03-05 |
| 2023-09-30 | $32.00M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $34.45M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $16.02M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $11.94M 10-K · filed 2025-03-10 |
| 2022-09-30 | $25.30M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $71.36M 10-Q · filed 2023-08-10 |
| 2021-12-31 | $56.28M 10-K · filed 2024-03-07 |
| 2018-09-30 | $20.29M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $27.63M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $30.25M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $37.69M 10-Q · filed 2018-11-08 |
| 2017-09-30 | $17.51M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $20.50M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $24.66M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $22.93M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |